Julio Martin-Sanchez

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

SUBCUTANEOUS VERSUS INTRAVENOUS TOCILIZUMAB IN AORTITIS ASSOCIATED WITH GIANT CELL ARTERITIS: MULTICENTER STUDY OF 196 PATIENTS.

SUBCUTANEOUS VERSUS INTRAVENOUS TOCILIZUMAB IN AORTITIS ASSOCIATED WITH GIANT CELL ARTERITIS: MULTICENTER STUDY OF 196 PATIENTS.

Journal: Arthritis care & research

Published: August 26, 2025

Subcutaneous Versus Intravenous Tocilizumab in Aortitis Associated With Giant Cell Arteritis: Multicenter Study of 196 Patients.

Subcutaneous Versus Intravenous Tocilizumab in Aortitis Associated With Giant Cell Arteritis: Multicenter Study of 196 Patients.

Journal: Arthritis care & research

Published: August 26, 2025

Epidemiology of major and minor relapses in giant cell arteritis according to EULAR definitions: insights from the ARTESER registry.

Epidemiology of major and minor relapses in giant cell arteritis according to EULAR definitions: insights from the ARTESER registry.

Journal: Rheumatology (Oxford, England)

Published: January 05, 2025

Situational analysis of interventional rheumatology in Spain: Multicenter observational study.

Situational analysis of interventional rheumatology in Spain: Multicenter observational study.

Journal: Reumatologia clinica

Published: October 21, 2024

18F-FDG-PET/CT Scan for Detection of Large Vessel Involvement in Giant Cell Arteritis: Arteser Spanish Registry.

18F-FDG-PET/CT Scan for Detection of Large Vessel Involvement in Giant Cell Arteritis: Arteser Spanish Registry.

Journal: Journal of clinical medicine

Published: September 09, 2024

Mortality in patients with giant cell arteritis in Spain: results from the ARTESER registry.

Mortality in patients with giant cell arteritis in Spain: results from the ARTESER registry.

Journal: Arthritis research & therapy

Published: August 28, 2024

Effectiveness Of Tocilizumab In Aortitis And Aneurysms Associated With Giant Cell Arteritis.

Effectiveness Of Tocilizumab In Aortitis And Aneurysms Associated With Giant Cell Arteritis.

Journal: European journal of internal medicine

Published: December 06, 2023

Visual manifestations in giant cell arteritis: identification of risk factors from the ARTESER Registry.

Visual manifestations in giant cell arteritis: identification of risk factors from the ARTESER Registry.

Journal: Rheumatology (Oxford, England)

Published: October 04, 2023

Optimisation of tocilizumab therapy in giant cell arteritis. A multicentre real-life study of 471 patients.

Optimisation of tocilizumab therapy in giant cell arteritis. A multicentre real-life study of 471 patients.

Journal: Clinical and experimental rheumatology

Published: June 12, 2022

Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients.

Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients.

Journal: Therapeutic advances in musculoskeletal disease

Published: February 26, 2022

Epidemiological and genetic features of anti-3‑hydroxy-3-methylglutaryl-CoA reductase necrotizing myopathy: Single-center experience and literature review.

Epidemiological and genetic features of anti-3‑hydroxy-3-methylglutaryl-CoA reductase necrotizing myopathy: Single-center experience and literature review.

Journal: European journal of internal medicine

Published: January 20, 2022

Correction: Ferraz-Amaro et al. SCORE2 Assessment in The Calculation of Cardiovascular Risk in Patients with Rheumatoid Arthritis. Diagnostics 2021, 11, 2363.

Correction: Ferraz-Amaro et al. SCORE2 Assessment in The Calculation of Cardiovascular Risk in Patients with Rheumatoid Arthritis. Diagnostics 2021, 11, 2363.

Journal: Diagnostics (Basel, Switzerland)

Published: December 29, 2021

Showing 1-12 of 18

Last Updated: 09/26/2026